Zobrazeno 1 - 10
of 345
pro vyhledávání: '"Masanori, Ikeda"'
Autor:
Ai Toyodome, Seiichi Mawatari, Hiromi Eguchi, Midori Takeda, Kotaro Kumagai, Ohki Taniyama, Sho Ijuin, Haruka Sakae, Kazuaki Tabu, Kohei Oda, Masanori Ikeda, Akio Ido
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-9 (2024)
Abstract Resistance-associated substitutions (RASs) of hepatitis C virus (HCV) affect the efficacy of direct-acting antivirals (DAAs). In this study, we aimed to clarify the susceptibility of the coexistence of nonstructural (NS) 5A Q24K/L28M/R30Q (o
Externí odkaz:
https://doaj.org/article/3fe6eb0227284a16be2ea8103fd1f582
Autor:
Mayumi Matsunaga, Yasunori Sato, Mizuho Nagao, Masanori Ikeda, Chikako Motomura, Makoto Kameda, Yukinori Yoshida, Akihiko Terada, Isao Miyairi, Takao Fujisawa
Publikováno v:
Allergology International, Vol 73, Iss 2, Pp 224-230 (2024)
Background: Maintaining good asthma control minimizes the risk of exacerbations and lung function decline and is a primary goal of asthma management. The Japanese Pediatric Asthma Guidelines (JPGL) employs different classification criteria for contro
Externí odkaz:
https://doaj.org/article/5c1c74b4605a4d34abf65a50ecbb1469
Autor:
Andreas Wollenberg, Masanori Ikeda, Chia-Yu Chu, Lawrence F. Eichenfield, Marieke M. B. Seyger, Apurva Prakash, Robinette Angle, Danting Zhu, Marco Pontes, Amy S. Paller
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Background Baricitinib, an oral selective Janus kinase inhibitor, improved clinical signs and symptoms of moderate-to-severe atopic dermatitis (AD) at week 16 in the phase 3 pediatric study BREEZE-AD-PEDS.Objective To assess longer-term efficacy and
Externí odkaz:
https://doaj.org/article/60c95020afe746ab9bb7dbef4c3fa42d
Autor:
Norito Katoh, Masanori Ikeda, Yukihiro Ohya, Hiroyuki Murota, Xiaofei Hu, John Liu, Hayato Niiyama, Takuya Sasaki, Eliza M. Raymundo, Hidehisa Saeki
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 1, Pp 213-232 (2023)
Abstract Introduction Upadacitinib is an oral Janus kinase inhibitor approved in multiple countries for moderate-to-severe atopic dermatitis (AD). Here we present long-term data for up to 3 years of continuous upadacitinib treatment in Japanese patie
Externí odkaz:
https://doaj.org/article/4c129502249d4a2e89226d27166dfd79
Autor:
Mitsuru Tsuge, Kenji Shigehara, Kazuhiro Uda, Seiji Kawano, Masaya Iwamuro, Yukie Saito, Masato Yashiro, Masanori Ikeda, Hirokazu Tsukahara
Publikováno v:
Allergy, Asthma & Clinical Immunology, Vol 19, Iss 1, Pp 1-8 (2023)
Abstract Background Non-esophageal eosinophilic gastrointestinal disorder (non-EoE-EGID) is a rare disease in which eosinophils infiltrate parts of the gastrointestinal tract other than the esophagus; however, the number of patients with non-EoE-EGID
Externí odkaz:
https://doaj.org/article/326769ace931473cb322eb2c39003387
Autor:
Nobukazu Hayashi, Masanori Ikeda, John Liu, Eliza Raymundo, Yingyi Liu, Takuya Sasaki, Kenshi Yamasaki
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 8, Pp 1817-1830 (2023)
Abstract Introduction Upadacitinib, an oral selective Janus kinase (JAK) inhibitor, is used to treat moderate-to-severe atopic dermatitis (AD). Acne is the most common treatment-emergent adverse event in patients with AD treated with upadacitinib. In
Externí odkaz:
https://doaj.org/article/5101dd4486ee4c679376a8dbf7190fd6
Autor:
Norito Katoh, MD, PhD, Yukihiro Ohya, MD, PhD, Hiroyuki Murota, MD, PhD, Masanori Ikeda, MD, PhD, Xiaofei Hu, PhD, Kimitoshi Ikeda, PhD, John Liu, MD, MS, Takuya Sasaki, Alvina D. Chu, MD, Henrique D. Teixeira, PhD, MBA, Hidehisa Saeki, MD, PhD
Publikováno v:
JAAD International, Vol 6, Iss , Pp 27-36 (2022)
Background: Systemic atopic dermatitis treatments that have acceptable safety are needed. Objective: To evaluate the safety of the oral Janus kinase inhibitor upadacitinib in combination with topical corticosteroids (TCSs) for the treatment of atopic
Externí odkaz:
https://doaj.org/article/3381acdcae8e440badf8a810bf6ba5e2
Publikováno v:
Allergy, Asthma & Clinical Immunology, Vol 17, Iss 1, Pp 1-8 (2021)
Abstract Background Jellyfish stings are known to induce allergic skin reactions; however, case reports of anaphylaxis after jellyfish ingestion have been increasing, especially in Asian countries. Some cases of anaphylaxis after jellyfish ingestion
Externí odkaz:
https://doaj.org/article/ee2bc9436d2b4cf1ab6cbe5d40a3e58a
Autor:
Daisuke Yasunari, Chikako Motomura, Toshiaki Kawano, Akihiro Takase, Masanori Ikeda, Teruaki Matsui, Mika Ogata, Shuichi Suzuki, Junichiro Tezuka, Mizuho Nagao, Natsuko Masumoto, Noriyuki Yanagida, Yukihiro Ohya
Publikováno v:
Arerugi: Japanese Journal of Allergology; 2024, Vol. 73 Issue 5, p406-415, 10p
Autor:
Norito Katoh, Yukihiro Ohya, Masanori Ikeda, Tamotsu Ebihara, Ichiro Katayama, Hidehisa Saeki, Naoki Shimojo, Akio Tanaka, Takeshi Nakahara, Mizuho Nagao, Michihiro Hide, Yuji Fujita, Takao Fujisawa, Masaki Futamura, Koji Masuda, Hiroyuki Murota, Kiwako Yamamoto-Hanada
Publikováno v:
Allergology International, Vol 69, Iss 3, Pp 356-369 (2020)
Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion, which is frequently encountered in clinical practice. Skin barrier dysfunction leads to enhanced skin irritability to non-specific stimuli and ep
Externí odkaz:
https://doaj.org/article/d7a17ecba69a4821b84c36a2ecac7547